{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:43:32Z","timestamp":1772772212077,"version":"3.50.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Norte2020","award":["Norte-01-0145-FEDER-000051"],"award-info":[{"award-number":["Norte-01-0145-FEDER-000051"]}]},{"name":"FUnda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["SFRH\/BD\/144719\/2019"],"award-info":[{"award-number":["SFRH\/BD\/144719\/2019"]}]},{"name":"FUnda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["PD\/BD\/145149\/2019"],"award-info":[{"award-number":["PD\/BD\/145149\/2019"]}]},{"name":"FUnda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["2021.07508.BD"],"award-info":[{"award-number":["2021.07508.BD"]}]},{"DOI":"10.13039\/501100006752","name":"Universidade do Porto","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006752","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:p>Peptides have a distinguished therapeutic potential for several chronic conditions, and more than 80 peptides exist in the global market. However, most of these marketed peptide drugs are currently delivered intravenously or subcutaneously due to their fast degradation and limited absorption through non-invasive routes. The pulmonary route is favored as a non-invasive route. Neonatal Fc receptor (FcRn) is expressed in adult human lungs and has a role in enhancing the pulmonary absorption of monoclonal antibodies. In this work, we developed and characterized candidate protein delivery systems for the pulmonary administration of peptides. The prepared bare and loaded zein nanoparticles (ZNPs), targeted, physically, and covalently PEGylated ZNPs showed hydrodynamic diameters between 137 and 155\u00a0nm and a narrow distribution index. Insulin, which was used as a protein model, showed an association efficiency of 72%, while the FcRn-targeted peptide conjugation efficiency was approximately 68%. The physically adsorbed poloxamer 407 on insulin-loaded ZNPs showed slower and controlled insulin release. The in vitro cell culture model consists of the NCI-H441 epithelial cell line, which confirmed its expression of the targeted receptor, FcRn. The safety of ZNPs was verified after incubation with both cell lines of the in vitro pulmonary model, namely NCI-H441 and HPMEC-ST1.6R, for 24\u00a0h. It was observed that targeted ZNPs enhanced insulin permeability by showing a higher apparent permeation coefficient than non-targeted ZNPs. Overall, both targeted PEGylated ZNPs showed to be suitable peptide carriers and adequately fit the demands of delivery systems designed for pulmonary administration.<\/jats:p>\n                <jats:p><jats:bold>Graphical Abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s13346-022-01286-4","type":"journal-article","created":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T01:15:07Z","timestamp":1672535707000},"page":"1699-1715","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Functionalized zein nanoparticles targeting neonatal Fc receptor to enhance lung absorption of peptides"],"prefix":"10.1007","volume":"13","author":[{"given":"Fatima","family":"Hameedat","sequence":"first","affiliation":[]},{"given":"Soraia","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Marques","sequence":"additional","affiliation":[]},{"given":"Sofia","family":"Dias","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5763-7553","authenticated-orcid":false,"given":"Bruno","family":"Sarmento","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,1,1]]},"reference":[{"key":"1286_CR1","doi-asserted-by":"publisher","unstructured":"Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat Rev Drug Discov.\u00a02021;204. Nature Publishing Group.\u00a02021;20:309\u201325. https:\/\/doi.org\/10.1038\/s41573-020-00135-8.","DOI":"10.1038\/s41573-020-00135-8"},{"key":"1286_CR2","doi-asserted-by":"publisher","unstructured":"Matthews AA, Ee PLR, Ge R. Developing inhaled protein therapeutics for lung diseases. Mol Biomed. Springer.\u00a02020;1:11. https:\/\/doi.org\/10.1186\/s43556-020-00014-z.","DOI":"10.1186\/s43556-020-00014-z"},{"key":"1286_CR3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.addr.2014.05.017","volume":"75","author":"C Loira-Pastoriza","year":"2014","unstructured":"Loira-Pastoriza C, Todoroff J, Vanbever R. Delivery strategies for sustained drug release in the lungs. Adv Drug Deliv Rev Elsevier. 2014;75:81\u201391. https:\/\/doi.org\/10.1016\/j.addr.2014.05.017.","journal-title":"Adv Drug Deliv Rev Elsevier"},{"key":"1286_CR4","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ijpharm.2013.11.042","volume":"461","author":"Y-B Wang","year":"2014","unstructured":"Wang Y-B, Watts AB, Peters JI, Williams RO. The impact of pulmonary diseases on the fate of inhaled medicines\u2013a review. Int J Pharm Elsevier. 2014;461:112\u201328. https:\/\/doi.org\/10.1016\/j.ijpharm.2013.11.042.","journal-title":"Int J Pharm Elsevier"},{"key":"1286_CR5","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1080\/10408444.2019.1584153","volume":"49","author":"K Ganguly","year":"2019","unstructured":"Ganguly K, Carlander U, Garessus EDG, Frid\u00e9n M, Eriksson UG, Tehler U, et al. Computational modeling of lung deposition of inhaled particles in chronic obstructive pulmonary disease (COPD) patients: identification of gaps in knowledge and data. Crit Rev Toxicol Taylor & Francis. 2019;49:160\u201373. https:\/\/doi.org\/10.1080\/10408444.2019.1584153.","journal-title":"Crit Rev Toxicol Taylor & Francis"},{"key":"1286_CR6","doi-asserted-by":"publisher","unstructured":"Sultan MH, Mahdi WA, Kwon YM. Insulin release from NPH insulin-loaded Pluronic\u00ae F127 hydrogel in the presence of simulated tissue enzyme activity. Process 2020, Vol 8, Page 1320. Multidisciplinary Digital Publishing Institute.\u00a02020;8:1320. https:\/\/doi.org\/10.3390\/PR8101320.","DOI":"10.3390\/PR8101320"},{"key":"1286_CR7","unstructured":"Goldberg T, Wong E. Afrezza (Insulin Human) Inhalation powder: a new inhaled insulin for the management of type-1 or type-2 diabetes mellitus. P T. MediMedia, USA.\u00a02015;40:735\u201341."},{"key":"1286_CR8","doi-asserted-by":"publisher","unstructured":"Hornby PJ, Cooper PR, Kliwinski C, Ragwan E, Mabus JR, Harman B, et al. Human and non-human primate intestinal FcRn expression and immunoglobulin G transcytosis. Pharm Res. Springer New York LLC.\u00a02014;31:908\u201322. https:\/\/doi.org\/10.1007\/s11095-013-1212-3.","DOI":"10.1007\/s11095-013-1212-3"},{"key":"1286_CR9","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s10875-010-9468-4","volume":"30","author":"TT Kuo","year":"2010","unstructured":"Kuo TT, Baker K, Yoshida M, Qiao S-W, Aveson VG, Lencer WI, et al. Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol Springer. 2010;30:777\u201389. https:\/\/doi.org\/10.1007\/s10875-010-9468-4.","journal-title":"J Clin Immunol Springer"},{"key":"1286_CR10","doi-asserted-by":"publisher","unstructured":"Fan YY, Farrokhi V, Caiazzo T, Wang M, O\u2019Hara DM, Neubert H. Human FcRn tissue expression profile and half-life in PBMCs. Biomol.\u00a02019;9:373. Multidisciplinary Digital Publishing Institute.\u00a02019;9:373. https:\/\/doi.org\/10.3390\/BIOM9080373.","DOI":"10.3390\/BIOM9080373"},{"key":"1286_CR11","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1093\/HUMREP\/DEH896","volume":"20","author":"SC Low","year":"2005","unstructured":"Low SC, Nunes SL, Bitonti AJ, Dumont JA. Oral and pulmonary delivery of FSH\u2013Fc fusion proteins via neonatal Fc receptor-mediated transcytosis. Hum Reprod Oxford Academic. 2005;20:1805\u201313. https:\/\/doi.org\/10.1093\/HUMREP\/DEH896.","journal-title":"Hum Reprod Oxford Academic"},{"key":"1286_CR12","doi-asserted-by":"publisher","unstructured":"Liang W, Pan HW, Vllasaliu D, Lam JKW. Pulmonary delivery of biological drugs. Pharm 2020;12:1025. Multidisciplinary Digital Publishing Institute.\u00a02020;12:1025. https:\/\/doi.org\/10.3390\/PHARMACEUTICS12111025.","DOI":"10.3390\/PHARMACEUTICS12111025"},{"key":"1286_CR13","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jconrel.2014.10.003","volume":"196","author":"L Guilleminault","year":"2014","unstructured":"Guilleminault L, Azzopardi N, Arnoult C, Sobilo J, Herv\u00e9 V, Montharu J, et al. Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system. J Control Release Elsevier. 2014;196:344\u201354. https:\/\/doi.org\/10.1016\/j.jconrel.2014.10.003.","journal-title":"J Control Release Elsevier"},{"key":"1286_CR14","doi-asserted-by":"publisher","unstructured":"Azevedo C, Pinto S, Benjakul S, Nilsen J, Santos HA, Traverso G, et al. Prevention of diabetes-associated fibrosis: strategies in FcRn-targeted nanosystems for oral drug delivery. Adv Drug Deliv Rev. Elsevier.\u00a02021;175:113778. https:\/\/doi.org\/10.1016\/j.addr.2021.04.016.","DOI":"10.1016\/j.addr.2021.04.016"},{"key":"1286_CR15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ijpharm.2013.02.031","volume":"447","author":"F Depreter","year":"2013","unstructured":"Depreter F, Pilcer G, Amighi K. Inhaled proteins: challenges and perspectives. Int J Pharm Elsevier. 2013;447:251\u201380. https:\/\/doi.org\/10.1016\/j.ijpharm.2013.02.031.","journal-title":"Int J Pharm Elsevier"},{"key":"1286_CR16","doi-asserted-by":"publisher","unstructured":"Abdelsalam AM, Somaida A, Ayoub AM, Alsharif FM, Preis E, Wojcik M, et al. Surface-tailored zein nanoparticles: strategies and applications. Pharmaceutics. Multidisciplinary Digital Publishing Institute.\u00a02021;1354. https:\/\/doi.org\/10.3390\/pharmaceutics13091354","DOI":"10.3390\/pharmaceutics13091354"},{"key":"1286_CR17","doi-asserted-by":"publisher","unstructured":"Labib G. Overview on zein protein: a promising pharmaceutical excipient in drug delivery systems and tissue engineering. https:\/\/doi.org\/10.1080\/1742524720171349752. Taylor & Francis.\u00a02017;15:65\u201375. https:\/\/doi.org\/10.1080\/17425247.2017.1349752.","DOI":"10.1080\/1742524720171349752 10.1080\/17425247.2017.1349752"},{"key":"1286_CR18","doi-asserted-by":"publisher","unstructured":"Reboredo C, Gonz\u00e1lez-Navarro CJ, Mart\u00ednez-L\u00f3pez AL, Mart\u00ednez-Oh\u00e1rriz C, Sarmento B, Irache JM. Zein-based nanoparticles as oral carriers for insulin delivery. Pharmaceutics. Multidisciplinary Digital Publishing Institute.\u00a02021;14:39. https:\/\/doi.org\/10.3390\/pharmaceutics14010039.","DOI":"10.3390\/pharmaceutics14010039"},{"key":"1286_CR19","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ijbiomac.2019.07.030","volume":"138","author":"G Heep","year":"2019","unstructured":"Heep G, Almeida A, Marcano R, Vieira D, Mainardes RM, Khalil NM, et al. Zein-casein-lysine multicomposite nanoparticles are effective in modulate the intestinal permeability of ferulic acid. Int J Biol Macromol Elsevier. 2019;138:244\u201351. https:\/\/doi.org\/10.1016\/j.ijbiomac.2019.07.030.","journal-title":"Int J Biol Macromol Elsevier"},{"key":"1286_CR20","doi-asserted-by":"publisher","unstructured":"Nunes R, Bai\u00e3o A, Monteiro D, das Neves J, Sarmento B. Zein nanoparticles as low-cost, safe, and effective carriers to improve the oral bioavailability of resveratrol. Drug Deliv Transl Res. Springer.\u00a02020;10:826\u201337. https:\/\/doi.org\/10.1007\/s13346-020-00738-z.","DOI":"10.1007\/s13346-020-00738-z"},{"key":"1286_CR21","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s13346-020-00796-3","volume":"10","author":"L Inchaurraga","year":"2020","unstructured":"Inchaurraga L, Mart\u00ednez-L\u00f3pez AL, Martin-Arbella N, Irache JM. Zein-based nanoparticles for the oral delivery of insulin. Drug Deliv Transl Res. 2020;10:1601\u201311. https:\/\/doi.org\/10.1007\/s13346-020-00796-3.","journal-title":"Drug Deliv Transl Res"},{"key":"1286_CR22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.actbio.2019.04.037","volume":"91","author":"A Costa","year":"2019","unstructured":"Costa A, de Souza C-W, Seabra V, Sarmento B, Lehr C-M. Triple co-culture of human alveolar epithelium, endothelium and macrophages for studying the interaction of nanocarriers with the air-blood barrier. Acta Biomater Elsevier. 2019;91:235\u201347. https:\/\/doi.org\/10.1016\/j.actbio.2019.04.037.","journal-title":"Acta Biomater Elsevier"},{"key":"1286_CR23","doi-asserted-by":"publisher","first-page":"6394","DOI":"10.1016\/j.bmc.2008.05.004","volume":"16","author":"AR Mezo","year":"2008","unstructured":"Mezo AR, McDonnell KA, Castro A, Fraley C. Structure-activity relationships of a peptide inhibitor of the human FcRn:human IgG interaction. Bioorganic Med Chem Bioorg Med Chem. 2008;16:6394\u2013405. https:\/\/doi.org\/10.1016\/j.bmc.2008.05.004.","journal-title":"Bioorganic Med Chem Bioorg Med Chem"},{"key":"1286_CR24","doi-asserted-by":"publisher","unstructured":"Sockolosky JT, Tiffany MR, Szoka FC. Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions. Proc Natl Acad Sci USA. National Academy of Sciences.\u00a02012;109:16095\u2013100. https:\/\/doi.org\/10.1073\/pnas.1208857109.","DOI":"10.1073\/pnas.1208857109"},{"key":"1286_CR25","doi-asserted-by":"publisher","unstructured":"Datta-Mannan A, Boyles J, Huang L, Jin ZY, Peariso A, Murphy AT, et al. Engineered FcRn binding fusion peptides significantly enhance the half-life of a fab domain in cynomolgus monkeys. Biotechnol J. John Wiley & Sons, Ltd; 2019;14:1800007. https:\/\/doi.org\/10.1002\/biot.201800007.","DOI":"10.1002\/biot.201800007"},{"key":"1286_CR26","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ejps.2008.09.008","volume":"36","author":"A Schoubben","year":"2009","unstructured":"Schoubben A, Blasi P, Giovagnoli S, Perioli L, Rossi C, Ricci M. Novel composite microparticles for protein stabilization and delivery. Eur J Pharm Sci Elsevier. 2009;36:226\u201334. https:\/\/doi.org\/10.1016\/j.ejps.2008.09.008.","journal-title":"Eur J Pharm Sci Elsevier"},{"key":"1286_CR27","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1023\/a:1018908705446","volume":"16","author":"R Fern\u00e1ndez-Urrusuno","year":"1999","unstructured":"Fern\u00e1ndez-Urrusuno R, Calvo P, Remu\u00f1\u00e1n-L\u00f3pez C, Vila-Jato JL, Alonso MJ. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res Springer. 1999;16:1576\u201381. https:\/\/doi.org\/10.1023\/a:1018908705446.","journal-title":"Pharm Res Springer"},{"key":"1286_CR28","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1021\/acs.molpharmaceut.7b00967","volume":"15","author":"D-K Ho","year":"2018","unstructured":"Ho D-K, Costa A, De Rossi C, de Souza C-W, Loretz B, Lehr C-M. Polysaccharide submicrocarrier for improved pulmonary delivery of poorly soluble anti-infective ciprofloxacin: preparation, characterization, and influence of size on cellular uptake. Mol Pharm Pergamon. 2018;15:1081\u201396. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00967.","journal-title":"Mol Pharm Pergamon"},{"key":"1286_CR29","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.molimm.2012.12.021","volume":"54","author":"O Kalashnyk","year":"2013","unstructured":"Kalashnyk O, Petrova Y, Lykhmus O, Mikhalovska L, Mikhalovsky S, Zhukova A, et al. Expression, function and cooperating partners of protease-activated receptor type 3 in vascular endothelial cells and B lymphocytes studied with specific monoclonal antibody. Mol Immunol Pergamon. 2013;54:319\u201326. https:\/\/doi.org\/10.1016\/j.molimm.2012.12.021.","journal-title":"Mol Immunol Pergamon"},{"key":"1286_CR30","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jconrel.2013.05.036","volume":"170","author":"D Liu","year":"2013","unstructured":"Liu D, Bimbo LM, M\u00e4kil\u00e4 E, Villanova F, Kaasalainen M, Herranz-Blanco B, et al. Co-delivery of a hydrophobic small molecule and a hydrophilic peptide by porous silicon nanoparticles. J Control Release Elsevier. 2013;170:268\u201378. https:\/\/doi.org\/10.1016\/j.jconrel.2013.05.036.","journal-title":"J Control Release Elsevier"},{"key":"1286_CR31","doi-asserted-by":"publisher","unstructured":"Pascoli M, de Lima R, Fraceto LF. Zein nanoparticles and strategies to improve colloidal stability: a mini-review. Front Chem. Frontiers Media S. A.\u00a02018;6:6. https:\/\/doi.org\/10.3389\/fchem.2018.00006.","DOI":"10.3389\/fchem.2018.00006"},{"key":"1286_CR32","doi-asserted-by":"publisher","unstructured":"Wu J, Zhao C, Lin W, Hu R, Wang Q, Chen H, et al. Binding characteristics between polyethylene glycol (PEG) and proteins in aqueous solution. J Mater Chem B. The Royal Society of Chemistry.\u00a02014;2:2983\u201392. https:\/\/doi.org\/10.1039\/C4TB00253A.","DOI":"10.1039\/C4TB00253A"},{"key":"1286_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.lwt.2021.112708","volume":"154","author":"Y Xu","year":"2022","unstructured":"Xu Y, Wei Z, Xue C, Huang Q. Assembly of zein\u2013polyphenol conjugates via carbodiimide method: evaluation of physicochemical and functional properties. LWT. 2022;154: 112708. https:\/\/doi.org\/10.1016\/j.lwt.2021.112708.","journal-title":"LWT"},{"key":"1286_CR34","doi-asserted-by":"publisher","unstructured":"Soe ZC, Ou W, Gautam M, Poudel K, Kim BK, Pham LM, et al. Development of folate-functionalized PEGylated zein nanoparticles for ligand-directed delivery of paclitaxel. Pharm 2019;11:562. Multidisciplinary Digital Publishing Institute.\u00a02019;11:562. https:\/\/doi.org\/10.3390\/PHARMACEUTICS11110562.","DOI":"10.3390\/PHARMACEUTICS11110562"},{"key":"1286_CR35","doi-asserted-by":"publisher","unstructured":"Meewan J, Somani S, Laskar P, Irving C, Mullin M, Woods S, et al. Limited impact of the protein corona on the cellular uptake of PEGylated zein micelles by melanoma cancer cells. Pharmaceutics. MDPI.\u00a02022;14. https:\/\/doi.org\/10.3390\/PHARMACEUTICS14020439\/S1.","DOI":"10.3390\/PHARMACEUTICS14020439\/S1"},{"key":"1286_CR36","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1039\/D1NR06512B","volume":"14","author":"W Tang","year":"2022","unstructured":"Tang W, Zhang Y, Zhu G. Pulmonary delivery of mucosal nanovaccines. Nanoscale The Royal Society of Chemistry. 2022;14:263\u201376. https:\/\/doi.org\/10.1039\/D1NR06512B.","journal-title":"Nanoscale The Royal Society of Chemistry"},{"key":"1286_CR37","doi-asserted-by":"publisher","unstructured":"Reboredo C, Gonz\u00e1lez-Navarro CJ, Mart\u00ednez-Oharriz C, Mart\u00ednez-L\u00f3pez AL, Irache JM. Preparation and evaluation of PEG-coated zein nanoparticles for oral drug delivery purposes. Int J Pharm. Elsevier; 2021;597:120287. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120287.","DOI":"10.1016\/j.ijpharm.2021.120287"},{"key":"1286_CR38","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1021\/mp2006455","volume":"9","author":"S Podaralla","year":"2012","unstructured":"Podaralla S, Averineni R, Alqahtani M, Perumal O. Synthesis of novel biodegradable methoxy poly(ethylene glycol)-zein micelles for effective delivery of curcumin. Mol Pharm American Chemical Society. 2012;9:2778\u201386. https:\/\/doi.org\/10.1021\/mp2006455.","journal-title":"Mol Pharm American Chemical Society"},{"key":"1286_CR39","doi-asserted-by":"publisher","unstructured":"Song R, Zhou Y, Li Y, Yang Z, Li F, Huang Q, et al. Preparation and characterization of mPEG-g-\u03b1-zein biohybrid micelles as a nano-carrier. J Appl Polym Sci. John Wiley & Sons, Ltd; 2015;132. https:\/\/doi.org\/10.1002\/APP.42555","DOI":"10.1002\/APP.42555"},{"key":"1286_CR40","doi-asserted-by":"publisher","unstructured":"Nunes R, Ara\u00fajo F, Tavares J, Sarmento B, das Neves J. Surface modification with polyethylene glycol enhances colorectal distribution and retention of nanoparticles. Eur J Pharm Biopharm. Elsevier; 2018;130:200\u20136. https:\/\/doi.org\/10.1016\/j.ejpb.2018.06.029.","DOI":"10.1016\/j.ejpb.2018.06.029"},{"key":"1286_CR41","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1039\/C9BM00759H","volume":"7","author":"M Melo","year":"2019","unstructured":"Melo M, Nunes R, Sarmento B, Das NJ. Colorectal distribution and retention of polymeric nanoparticles following incorporation into a thermosensitive enema. Biomater Sci Royal Society of Chemistry. 2019;7:3801\u201311. https:\/\/doi.org\/10.1039\/C9BM00759H.","journal-title":"Biomater Sci Royal Society of Chemistry"},{"key":"1286_CR42","doi-asserted-by":"publisher","unstructured":"Bodratti AM, Alexandridis P. Formulation of poloxamers for drug delivery. J Funct Biomater 2018, Vol 9, Page 11. Multidisciplinary Digital Publishing Institute; 2018;9:11. https:\/\/doi.org\/10.3390\/JFB9010011.","DOI":"10.3390\/JFB9010011"},{"key":"1286_CR43","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.addr.2017.08.010","volume":"124","author":"JT Huckaby","year":"2018","unstructured":"Huckaby JT, Lai SK. PEGylation for enhancing nanoparticle diffusion in mucus. Adv Drug Deliv Rev Elsevier. 2018;124:125\u201339. https:\/\/doi.org\/10.1016\/j.addr.2017.08.010.","journal-title":"Adv Drug Deliv Rev Elsevier"},{"key":"1286_CR44","doi-asserted-by":"publisher","unstructured":"Vijay Kumar Thakur MKT. Handbook of Polymers for Pharmaceutical Technologies [Internet]. Thakur VK, Thakur MK, editors. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2015. https:\/\/doi.org\/10.1002\/9781119041375.","DOI":"10.1002\/9781119041375"},{"key":"1286_CR45","doi-asserted-by":"publisher","first-page":"6791","DOI":"10.1016\/j.biomaterials.2011.04.082","volume":"32","author":"LJ Cruz","year":"2011","unstructured":"Cruz LJ, Tacken PJ, Fokkink R, Figdor CG. The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells. Biomaterials Elsevier. 2011;32:6791\u2013803. https:\/\/doi.org\/10.1016\/j.biomaterials.2011.04.082.","journal-title":"Biomaterials Elsevier"},{"key":"1286_CR46","doi-asserted-by":"publisher","first-page":"5648","DOI":"10.1021\/nn301630n","volume":"6","author":"S Hak","year":"2012","unstructured":"Hak S, Helgesen E, Hektoen HH, Huuse EM, Jarzyna PA, Mulder WJM, et al. The effect of nanoparticle polyethylene glycol surface density on ligand-directed tumor targeting studied in vivo by dual modality imaging. ACS Nano American Chemical Society. 2012;6:5648\u201358. https:\/\/doi.org\/10.1021\/nn301630n.","journal-title":"ACS Nano American Chemical Society"},{"key":"1286_CR47","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jconrel.2014.10.024","volume":"197","author":"X Han","year":"2015","unstructured":"Han X, Li Z, Sun J, Luo C, Li L, Liu Y, et al. Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation. J Control Release Elsevier. 2015;197:29\u201340. https:\/\/doi.org\/10.1016\/j.jconrel.2014.10.024.","journal-title":"J Control Release Elsevier"},{"key":"1286_CR48","doi-asserted-by":"publisher","unstructured":"Dai Q, Walkey C, Chan WCW. Polyethylene glycol backfilling mitigates the negative impact of the protein corona on nanoparticle cell targeting. Angew Chemie Int Ed. Angew Chem Int Ed Engl.\u00a02014;53:5093\u20136. https:\/\/doi.org\/10.1002\/anie.201309464.","DOI":"10.1002\/anie.201309464"},{"key":"1286_CR49","doi-asserted-by":"publisher","unstructured":"Narum SM, Le T, Le DP, Lee JC, Donahue ND, Yang W, et al. Passive targeting in nanomedicine: fundamental concepts, body interactions, and clinical potential. Nanoparticles Biomed Appl Elsevier.\u00a02020;37\u201353. https:\/\/doi.org\/10.1016\/B978-0-12-816662-8.00004-7.","DOI":"10.1016\/B978-0-12-816662-8.00004-7"},{"key":"1286_CR50","doi-asserted-by":"publisher","unstructured":"Sato K, Nagai J, Mitsui N, Ryoko Yumoto, Takano M. Effects of endocytosis inhibitors on internalization of human IgG by Caco-2 human intestinal epithelial cells. Life Sci. Pergamon.\u00a02009;85:800\u20137. https:\/\/doi.org\/10.1016\/j.lfs.2009.10.012.","DOI":"10.1016\/j.lfs.2009.10.012"},{"key":"1286_CR51","doi-asserted-by":"publisher","unstructured":"Martins JP, Liu D, Fontana F, Ferreira MPA, Correia A, Valentino S, et al. Microfluidic nanoassembly of bioengineered chitosan-modified FcRn-targeted porous silicon nanoparticles @ hypromellose acetate succinate for oral delivery of antidiabetic peptides. ACS Appl Mater Interfaces. Am Chem Soc.\u00a02018;10:44354\u201367. https:\/\/doi.org\/10.1021\/acsami.8b20821.","DOI":"10.1021\/acsami.8b20821"},{"key":"1286_CR52","doi-asserted-by":"publisher","unstructured":"Martins JP, D\u2019Auria R, Liu D, Fontana F, Ferreira MPA, Correia A, et al. Engineered multifunctional albumin-decorated porous silicon nanoparticles for FcRn translocation of insulin. Small. John Wiley & Sons, Ltd.\u00a02018;14:1800462. https:\/\/doi.org\/10.1002\/SMLL.201800462.","DOI":"10.1002\/SMLL.201800462"},{"key":"1286_CR53","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.bioactmat.2021.08.007","volume":"9","author":"JP Martins","year":"2022","unstructured":"Martins JP, Figueiredo P, Wang S, Espo E, Celi E, Martins B, et al. Neonatal Fc receptor-targeted lignin-encapsulated porous silicon nanoparticles for enhanced cellular interactions and insulin permeation across the intestinal epithelium. Bioact Mater Elsevier. 2022;9:299\u2013315. https:\/\/doi.org\/10.1016\/j.bioactmat.2021.08.007.","journal-title":"Bioact Mater Elsevier"},{"key":"1286_CR54","doi-asserted-by":"publisher","first-page":"578","DOI":"10.2133\/dmpk.dmpk-10-rg-067","volume":"25","author":"A Ishii-Watabe","year":"2010","unstructured":"Ishii-Watabe A, Saito Y, Suzuki T, Tada M, Ukaji M, Maekawa K, et al. Genetic polymorphisms of FCGRT encoding FcRn in a Japanese population and their functional analysis. Drug Metab Pharmacokinet Elsevier. 2010;25:578\u201387. https:\/\/doi.org\/10.2133\/dmpk.dmpk-10-rg-067.","journal-title":"Drug Metab Pharmacokinet Elsevier"},{"key":"1286_CR55","doi-asserted-by":"publisher","unstructured":"Ferguson DC, Blanco JG. Regulation of the human Fc-neonatal receptor alpha-chain gene FCGRT by MicroRNA-3181. Pharm Res. Springer New York LLC.\u00a02018;35:15. https:\/\/doi.org\/10.1007\/s11095-017-2294-0.","DOI":"10.1007\/s11095-017-2294-0"},{"key":"1286_CR56","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jconrel.2011.12.009","volume":"158","author":"D Vllasaliu","year":"2012","unstructured":"Vllasaliu D, Alexander C, Garnett M, Eaton M, Stolnik S. Fc-mediated transport of nanoparticles across airway epithelial cell layers. J Control Release Elsevier. 2012;158:479\u201386. https:\/\/doi.org\/10.1016\/j.jconrel.2011.12.009.","journal-title":"J Control Release Elsevier"},{"key":"1286_CR57","doi-asserted-by":"publisher","unstructured":"Bequignon E, Dhomm\u00e9e C, Angely C, Thomas L, Bottier M, Escudier E, et al. FcRn-dependent transcytosis of monoclonal antibody in human nasal epithelial cells in vitro: a prerequisite for a new delivery route for therapy? Int J Mol Sci.\u00a02019;20:1379. Multidisciplinary Digital Publishing Institute.\u00a02019;20:1379. https:\/\/doi.org\/10.3390\/IJMS20061379.","DOI":"10.3390\/IJMS20061379"},{"key":"1286_CR58","doi-asserted-by":"publisher","unstructured":"Sousa F, Castro P. Cell-based in vitro models for\u00a0nasal permeability studies. In: Sarmento B, editor. Concepts model drug permeability stud cell tissue based Vitr Cult Model. Sawston: Woodhead Publishing.\u00a02016;83\u2013100. https:\/\/doi.org\/10.1016\/B978-0-08-100094-6.00006-7.","DOI":"10.1016\/B978-0-08-100094-6.00006-7"},{"key":"1286_CR59","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1165\/rcmb.2009-0453OC","volume":"44","author":"A Dvorak","year":"2011","unstructured":"Dvorak A, Tilley AE, Shaykhiev R, Wang R, Crystal RG. Do airway epithelium air\u2013liquid cultures represent the in vivo airway epithelium transcriptome? Am J Respir Cell Mol Biol. American Thoracic Society. 2011;44:465\u201373. https:\/\/doi.org\/10.1165\/rcmb.2009-0453OC.","journal-title":"American Thoracic Society"},{"key":"1286_CR60","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s11095-014-1494-0","volume":"32","author":"ME Kreft","year":"2015","unstructured":"Kreft ME, Jerman UD, Lasi\u010d E, Lani\u0161nik Ri\u017ener T, Hevir-Kene N, Peternel L, et al. The characterization of the human nasal epithelial cell line RPMI 2650 under different culture conditions and their optimization for an appropriate in vitro nasal model. Pharm Res Springer. 2015;32:665\u201379. https:\/\/doi.org\/10.1007\/s11095-014-1494-0.","journal-title":"Pharm Res Springer"},{"key":"1286_CR61","unstructured":"ISO 10993\u20135:2009 - Biological evaluation of medical devices \u2014 Part 5: Tests for in vitro cytotoxicity. 2009;34."},{"key":"1286_CR62","doi-asserted-by":"publisher","unstructured":"Ren H, Birch NP, Suresh V. An optimised human cell culture model for alveolar epithelial transport. PLoS One. Pub Lib Sci.\u00a02016;11:e0165225. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0165225.","DOI":"10.1371\/JOURNAL.PONE.0165225"},{"key":"1286_CR63","doi-asserted-by":"publisher","unstructured":"Dai Q, Bertleff\u2010Zieschang N, Braunger JA, Bj\u00f6rnmalm M, Cortez\u2010Jugo C, Caruso F. Particle targeting in complex biological media. Adv Healthc Mater. John Wiley & Sons, Ltd.\u00a02018;7:1700575. https:\/\/doi.org\/10.1002\/adhm.201700575.","DOI":"10.1002\/adhm.201700575"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-022-01286-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-022-01286-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-022-01286-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T12:19:05Z","timestamp":1682338745000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-022-01286-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1286"],"URL":"https:\/\/doi.org\/10.1007\/s13346-022-01286-4","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,1]]},"assertion":[{"value":"21 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed according to the principles of the Declaration of Helsinki. In addition, the commercially available cell lines were only included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors declare that they have read the final version of the manuscript and have agreed to its submission for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}